Viewpoint: leprosy after the year 2000.
Naafs
B
B
Leiden University Medical Centre (LUMC), Leiden, The Netherlands. benaafs@dds.nl
D002991:Clofazimine / Q000009:adverse effects; D004359:Drug Therapy, Combination; D014943:Global Health; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000139:chemically induced; D007917:Leprostatic Agents / Q000009:adverse effects; D007918:Leprosy / Q000188:drug therapy / Q000453:epidemiology* / Q000517:prevention & control*; D015995:Prevalence; D011634:Public Health / Q000639:trends*; D012293:Rifampin / Q000009:adverse effects; D012867:Skin / Q000294:innervation
D007917:Leprostatic Agents; D002991:Clofazimine; D012293:Rifampin